Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03882528 · ClinicalTrials.gov registry record · Phase 1

Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54

A Phase 1 study of Malaria,Falciparum, sponsored by U.S. Army Medical Research and Development Command.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT03882528 is a Phase 1 study of Malaria,Falciparum that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03882528, a Phase 1 study of Malaria,Falciparum, has completed, sponsored by U.S. Army Medical Research and Development Command.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

Objectives: Primary: • To characterize the infectivity of the new lot of Plasmodium falciparum strain 3D7 within the standard WRAIR CHMI model as compared to the current lot (historical data) Secondary: * To assess safety of the new lot of P falciparum parasites * To assess the kinetics of detecting parasitemia and parasite clearance by quantitative polymerase chain reaction (qPCR) as compared to blood smear * To obtain plasma samples to restore the testing control pool for malaria serology testing and for future malaria research

Conditions Studied

Interventions

  • BIOLOGICAL Plasmodium falciparum malaria parasite

Study Locations (1)

Maryland

  • Walter Reed Army Institute of Research - Silver Spring

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2019-03-04
Est. Completion 2019-05-16
Phase Phase 1

What the Registry Record Tells You About NCT03882528

The ClinicalTrials.gov registry entry for NCT03882528 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malaria,Falciparum appearing as the primary indexed condition, and to 1 intervention - of which Plasmodium falciparum malaria parasite is the first listed.

NCT03882528 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03882528 about?

NCT03882528 is a clinical study titled "Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54". Objectives: Primary: • To characterize the infectivity of the new lot of Plasmodium falciparum strain 3D7 within the standard WRAIR CHMI model as compared to the current lot (historical data) Secondary: * To assess safety of the new lot of P falciparum parasites * To assess the kinetics of detec...

What is the current status of trial NCT03882528?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-03-04. Estimated completion is 2019-05-16.

What conditions does trial NCT03882528 study?

This clinical trial studies the following conditions: Malaria,Falciparum.

What interventions are being tested in trial NCT03882528?

The interventions under investigation include: Plasmodium falciparum malaria parasite (BIOLOGICAL).

Who is sponsoring clinical trial NCT03882528?

This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03882528 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.